PTPN11 and liver cancer: Then, and this is crucial, SHP2 inhibitors can boost the antitumor innate immune system in liver cancer driven by RTKs by upregulating interferon-β Secretion, downregulating inflammatory cytokines, and inhibiting the chemokine receptor 5 signaling axis (104).